Loreto Cuitino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Loreto Cuitino has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Cristhian A. Urzua
Laboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, Chile.
5 shared publications Rodrigo A. Valenzuela
Laboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, Universidad de Chile, Santiago, Chile
4 shared publications- Carolina Llanos
Departamento de Inmunología Clínica y Reumatología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
3 shared publications Claudio Retamal
2 shared publicationsFabian Vega-Tapia
Laboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, Chile
2 shared publicationsGinny G. Farías
Cell Biology and Metabolism Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
2 shared publications
Latest Publications
- 12 June 2026
- Published by Springer Nature in Eye
- Vol. 40 (12) , 1942-1955
Vogt-Koyanagi-Harada disease frequency around the globe: a systematic review and meta-analysis
Vogt-Koyanagi-Harada (VKH) disease has been historically associated with specific ethnic groups, suggesting an underlying susceptibility. Prior to this study, no meta-analysis had synthesized the global epidemiology of VKH, and therefore, information on its geographic distribution remained incomplete. The present study aims to determine the global distribution of VKH disease diagnosis in individuals presenting with uveitis. A systematic review and meta-analysis of quantitative studies published between 2001 and 2025 in PubMed, SciELO, and LILACS was conducted following PRISMA-P guidelines. Case reports were excluded. Risk of bias was assessed using the Murad assessment tool for case series. A random-effects model was used to pool frequency estimates with 95% confidence intervals and prediction intervals. Of 7153 articles identified, 258 studies were analyzed, spanning six continents and 44 countries. The estimated frequency of VKH among uveitis cases was 5.11% (CI:4.31-5.90%; PI: 0.00-15.18%) overall, with predominance of females. When subgrouped into pediatric and adult populations, the estimated frequency was 2.43% (CI:1.83-3.02%; PI: 0.00-6.38%) and 6.15% (CI:4.06-8.24%; PI: 0.00-19.77%), respectively. Frequencies varied across regions, with higher rates reported in Southeast Asia, East Asia, and Africa, and lower rates in North America, Europe, and Oceania. Regarding the quality evaluation, most studies were considered as medium-high quality (162/169, 96%). This systematic review and meta-analysis support the existence of geographical differences in VKH disease expression and the need for additional epidemiological research, particularly in underrepresented regions. These findings should be interpreted in the context of methodological heterogeneity and potential publication and geographic bias.
- 12 June 2026
- Published by Springer Nature in Eye
- Vol. 40 (12) , 1942-1955
Vogt-Koyanagi-Harada disease frequency around the globe: a systematic review and meta-analysis
Vogt-Koyanagi-Harada (VKH) disease has been historically associated with specific ethnic groups, suggesting an underlying susceptibility. Prior to this study, no meta-analysis had synthesized the global epidemiology of VKH, and therefore, information on its geographic distribution remained incomplete. The present study aims to determine the global distribution of VKH disease diagnosis in individuals presenting with uveitis. A systematic review and meta-analysis of quantitative studies published between 2001 and 2025 in PubMed, SciELO, and LILACS was conducted following PRISMA-P guidelines. Case reports were excluded. Risk of bias was assessed using the Murad assessment tool for case series. A random-effects model was used to pool frequency estimates with 95% confidence intervals and prediction intervals. Of 7153 articles identified, 258 studies were analyzed, spanning six continents and 44 countries. The estimated frequency of VKH among uveitis cases was 5.11% (CI:4.31-5.90%; PI: 0.00-15.18%) overall, with predominance of females. When subgrouped into pediatric and adult populations, the estimated frequency was 2.43% (CI:1.83-3.02%; PI: 0.00-6.38%) and 6.15% (CI:4.06-8.24%; PI: 0.00-19.77%), respectively. Frequencies varied across regions, with higher rates reported in Southeast Asia, East Asia, and Africa, and lower rates in North America, Europe, and Oceania. Regarding the quality evaluation, most studies were considered as medium-high quality (162/169, 96%). This systematic review and meta-analysis support the existence of geographical differences in VKH disease expression and the need for additional epidemiological research, particularly in underrepresented regions. These findings should be interpreted in the context of methodological heterogeneity and potential publication and geographic bias.
- Open Access
- 10 May 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
miRNA Landscape in Pathogenesis and Treatment of Vogt–Koyanagi–Harada Disease
MiRNAs, one of the members of the noncoding RNA family, are regulators of gene expression in inflammatory and autoimmune diseases. Changes in miRNA pool expression have been associated with differentiation of CD4+ T cells toward an inflammatory phenotype and with loss of self-tolerance in autoimmune diseases. Vogt–Koyanagi–Harada (VKH) disease is a chronic multisystemic pathology, affecting the uvea, inner ear, central nervous system, and skin. Several lines of evidence support an autoimmune etiology for VKH, with loss of tolerance against retinal pigmented epithelium-related self-antigens. This deleterious reaction is characterized by exacerbated inflammation, due to an aberrant TH1 and TH17 polarization and secretion of their proinflammatory hallmark cytokines interleukin 6 (IL-6), IL-17, interferon γ, and tumor necrosis factor α, and an impaired CD4+ CD25high FoxP3+ regulatory T cell function. To restrain inflammation, VKH is pharmacologically treated with corticosteroids and immunosuppressive drugs as first and second line of therapy, respectively. Changes in the expression of miRNAs related to immunoregulatory pathways have been associated with VKH development, whereas some genetic variants of miRNAs have been found to be risk modifiers of VKH. Furthermore, the drugs commonly used in VKH treatment have great influence on miRNA expression, including those miRNAs associated to VKH disease. This relationship between response to therapy and miRNA regulation suggests that these small noncoding molecules might be therapeutic targets for the development of more effective and specific pharmacological therapy for VKH. In this review, we discuss the latest evidence regarding regulation and alteration of miRNA associated with VKH disease and its treatment.
- 10 May 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Open AccessmiRNA Landscape in Pathogenesis and Treatment of Vogt–Koyanagi–Harada Disease
MiRNAs, one of the members of the noncoding RNA family, are regulators of gene expression in inflammatory and autoimmune diseases. Changes in miRNA pool expression have been associated with differentiation of CD4+ T cells toward an inflammatory phenotype and with loss of self-tolerance in autoimmune diseases. Vogt–Koyanagi–Harada (VKH) disease is a chronic multisystemic pathology, affecting the uvea, inner ear, central nervous system, and skin. Several lines of evidence support an autoimmune etiology for VKH, with loss of tolerance against retinal pigmented epithelium-related self-antigens. This deleterious reaction is characterized by exacerbated inflammation, due to an aberrant TH1 and TH17 polarization and secretion of their proinflammatory hallmark cytokines interleukin 6 (IL-6), IL-17, interferon γ, and tumor necrosis factor α, and an impaired CD4+ CD25high FoxP3+ regulatory T cell function. To restrain inflammation, VKH is pharmacologically treated with corticosteroids and immunosuppressive drugs as first and second line of therapy, respectively. Changes in the expression of miRNAs related to immunoregulatory pathways have been associated with VKH development, whereas some genetic variants of miRNAs have been found to be risk modifiers of VKH. Furthermore, the drugs commonly used in VKH treatment have great influence on miRNA expression, including those miRNAs associated to VKH disease. This relationship between response to therapy and miRNA regulation suggests that these small noncoding molecules might be therapeutic targets for the development of more effective and specific pharmacological therapy for VKH. In this review, we discuss the latest evidence regarding regulation and alteration of miRNA associated with VKH disease and its treatment.
- 12 April 2021
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 259 (10) , 2905-2911
Association of retinal detachment with age 50 years or younger at onset in patients with acute retinal necrosis
Background Due to the guarded prognosis of acute retinal necrosis (ARN), it is relevant to develop a strategy to early categorize those patients in a higher risk of worse outcomes. The purpose of this study is to describe clinical features and predictive factors for retinal detachment (RD) in patients with ARN. Methods Retrospective observational case series of 34 adult patients (38 eyes) with ARN examined between January 2005 and July 2015 in the National Eye Institute (Bethesda, USA), the Department of Ophthalmology, University of Chile (Santiago, Chile), and APEC (CDMX, Mexico). Results A total of 16 males and 18 females with a mean age at presentation of 44.5 ± 16.8 years were included. Twenty-seven patients (79.4%) received intravenous acyclovir as first-line treatment, and 7 patients received either oral antiviral (4 patients) or oral plus intravitreal antiviral (3 patients). All subjects were treated with prednisone, with a mean initial dose of 57.7 ± 16.3 mg per day. Seventeen patients (50.0%) developed retinal detachment. An association of retinal detachment with age at onset was observed (p = 0.04), with patients younger than 50 years presenting a higher risk (OR = 14.86, p = 0.0009). Additionally, patients in this higher risk group had more inflammation in both anterior chamber and vitreous (p = 0.04 and 0.03, respectively). No other predictive factor for retinal detachment was found in the present study. Conclusions RD represents an important complication in patients with ARN. Younger patients may be at higher risk of this complication, possibly secondary to the presence of a higher level of inflammation.
- 12 April 2021
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 259 (10) , 2905-2911
Association of retinal detachment with age 50 years or younger at onset in patients with acute retinal necrosis
Background Due to the guarded prognosis of acute retinal necrosis (ARN), it is relevant to develop a strategy to early categorize those patients in a higher risk of worse outcomes. The purpose of this study is to describe clinical features and predictive factors for retinal detachment (RD) in patients with ARN. Methods Retrospective observational case series of 34 adult patients (38 eyes) with ARN examined between January 2005 and July 2015 in the National Eye Institute (Bethesda, USA), the Department of Ophthalmology, University of Chile (Santiago, Chile), and APEC (CDMX, Mexico). Results A total of 16 males and 18 females with a mean age at presentation of 44.5 ± 16.8 years were included. Twenty-seven patients (79.4%) received intravenous acyclovir as first-line treatment, and 7 patients received either oral antiviral (4 patients) or oral plus intravitreal antiviral (3 patients). All subjects were treated with prednisone, with a mean initial dose of 57.7 ± 16.3 mg per day. Seventeen patients (50.0%) developed retinal detachment. An association of retinal detachment with age at onset was observed (p = 0.04), with patients younger than 50 years presenting a higher risk (OR = 14.86, p = 0.0009). Additionally, patients in this higher risk group had more inflammation in both anterior chamber and vitreous (p = 0.04 and 0.03, respectively). No other predictive factor for retinal detachment was found in the present study. Conclusions RD represents an important complication in patients with ARN. Younger patients may be at higher risk of this complication, possibly secondary to the presence of a higher level of inflammation.
- 4 September 2020
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 30 (1) , 174-179
Definition of Uveitis Refractory to Treatment: A Systematic Review in the Absence of a Consensus
To evaluate the different definition of refractoriness in uveitis in the literature. We systematically searched the literature in order to identify definitions of refractory noninfectious uveitis i...
- 4 September 2020
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 30 (1) , 174-179
Definition of Uveitis Refractory to Treatment: A Systematic Review in the Absence of a Consensus
To evaluate the different definition of refractoriness in uveitis in the literature. We systematically searched the literature in order to identify definitions of refractory noninfectious uveitis i...
- Open Access
- 8 May 2020
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 655
New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview
Non-Infectious uveitis is a group of disorders characterized by intraocular inflammation at different levels of the eye and are a leading cause of irreversible blindness in working-age population in the developed world. The goal of uveitis treatment is to control inflammation, prevent recurrences and preserve vision, as well as minimizing the adverse effects of medication. Currently, the standard of care for non-infectious uveitis includes the administration of corticosteroids (CS) as first line agents, but in some patients a more aggressive therapy is required. This includes synthetic immunosuppressants such as metothrexate, mycophenolate mofetil and azathioprine, calcineurinic inhibitors (cyclosporine, tacrolimus) and alkylating agents (cyclophosphamide, chlorambucil). Nevertheless, some patients become intolerant or refractory to CS and conventional immunosuppressive treatment. In these patients, biologic therapy has arisen as an effective therapy. Among the most evaluated treatments, TNF-α inhibitors, IL blockers and anti-CD20 therapy have emerged. In this regard, anti-TNF agents (infliximab and adalimumab), have shown the strongest results in terms of favorable outcomes. In this review, we will discuss recent evidence concerning to the effectiveness of biologic therapy, and present new therapeutic approaches directed against immune components as potential novel therapies for non-infectious uveitis.
- 8 May 2020
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 655
Open AccessNew Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview
Non-Infectious uveitis is a group of disorders characterized by intraocular inflammation at different levels of the eye and are a leading cause of irreversible blindness in working-age population in the developed world. The goal of uveitis treatment is to control inflammation, prevent recurrences and preserve vision, as well as minimizing the adverse effects of medication. Currently, the standard of care for non-infectious uveitis includes the administration of corticosteroids (CS) as first line agents, but in some patients a more aggressive therapy is required. This includes synthetic immunosuppressants such as metothrexate, mycophenolate mofetil and azathioprine, calcineurinic inhibitors (cyclosporine, tacrolimus) and alkylating agents (cyclophosphamide, chlorambucil). Nevertheless, some patients become intolerant or refractory to CS and conventional immunosuppressive treatment. In these patients, biologic therapy has arisen as an effective therapy. Among the most evaluated treatments, TNF-α inhibitors, IL blockers and anti-CD20 therapy have emerged. In this regard, anti-TNF agents (infliximab and adalimumab), have shown the strongest results in terms of favorable outcomes. In this review, we will discuss recent evidence concerning to the effectiveness of biologic therapy, and present new therapeutic approaches directed against immune components as potential novel therapies for non-infectious uveitis.
- Open Access
- 13 December 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 2868
Heme-Oxygenase-1 Is Decreased in Circulating Monocytes and Is Associated With Impaired Phagocytosis and ROS Production in Lupus Nephritis
Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE). Based on studies showing the potential role of heme oxygenase-1 (HO-1), an enzyme that catalyzes the degradation of heme and has anti-inflammatory properties in SLE development, we decided to explore HO-1 in LN. Accordingly, we evaluated HO-1 levels and function in circulating and infiltrating monocytes and neutrophils of LN patients. HO-1 levels were assessed in peripheral monocytes of LN patients and controls by flow cytometry and immunofluorescence microscopy. Phagocytosis and the production of reactive oxygen species (ROS) were evaluated to determine the effect of HO-1 in monocyte function. In addition, renal biopsies with proliferative LN were used to identify HO-1 in infiltrating cells and renal tissue by immunofluorescence and immunohistochemistry. Biopsies of healthy controls (HC) and patients who underwent nephrectomy were included as controls. Circulating pro-inflammatory monocytes and activated neutrophils were increased in LN patients. HO-1 levels were decreased in all subsets of monocytes and in activated neutrophils. LN monocytes showed increased phagocytosis and higher production of ROS than those of HC. When HO-1 was induced, phagocytosis and ROS levels became similar to those of HC. HO-1 was mostly expressed in renal tubular epithelial cells (RTEC). Renal tissue of LN patients showed lower levels of HO-1 than HC, whereas infiltrating immune cells of LN showed lower levels of HO-1 than biopsies of patients who had renal surgery. HO-1 is decreased in circulating monocytes and activated neutrophils of LN patients. HO-1 levels modulate the phagocytosis of LN monocytes and ROS production. HO-1 expression in RTEC might be an attempt of self-protection from inflammation.
- 13 December 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 2868
Open AccessHeme-Oxygenase-1 Is Decreased in Circulating Monocytes and Is Associated With Impaired Phagocytosis and ROS Production in Lupus Nephritis
Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE). Based on studies showing the potential role of heme oxygenase-1 (HO-1), an enzyme that catalyzes the degradation of heme and has anti-inflammatory properties in SLE development, we decided to explore HO-1 in LN. Accordingly, we evaluated HO-1 levels and function in circulating and infiltrating monocytes and neutrophils of LN patients. HO-1 levels were assessed in peripheral monocytes of LN patients and controls by flow cytometry and immunofluorescence microscopy. Phagocytosis and the production of reactive oxygen species (ROS) were evaluated to determine the effect of HO-1 in monocyte function. In addition, renal biopsies with proliferative LN were used to identify HO-1 in infiltrating cells and renal tissue by immunofluorescence and immunohistochemistry. Biopsies of healthy controls (HC) and patients who underwent nephrectomy were included as controls. Circulating pro-inflammatory monocytes and activated neutrophils were increased in LN patients. HO-1 levels were decreased in all subsets of monocytes and in activated neutrophils. LN monocytes showed increased phagocytosis and higher production of ROS than those of HC. When HO-1 was induced, phagocytosis and ROS levels became similar to those of HC. HO-1 was mostly expressed in renal tubular epithelial cells (RTEC). Renal tissue of LN patients showed lower levels of HO-1 than HC, whereas infiltrating immune cells of LN showed lower levels of HO-1 than biopsies of patients who had renal surgery. HO-1 is decreased in circulating monocytes and activated neutrophils of LN patients. HO-1 levels modulate the phagocytosis of LN monocytes and ROS production. HO-1 expression in RTEC might be an attempt of self-protection from inflammation.
- Top Cited PapersOpen Access
- 15 April 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 772
Innate Immune Cells' Contribution to Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the presence of autoantibodies against nuclear antigens, immune complex deposition and tissue damage in the kidneys, skin, heart and lung. Because of the pathogenic role of antinuclear antibodies and autoreactive T cells in SLE, extensive efforts have been made to demonstrate how B cells act as antibody-producing or as antigen-presenting cells that can prime autoreactive T cell activation. With the discovery of new innate immune cells and inflammatory mediators, innate immunity is emerging as a key player in disease pathologies. Recent work over the last decade has highlighted the importance of innate immune cells and molecules in promoting and potentiating SLE. In this review, we discuss recent evidence of the involvement of different innate immune cells and pathways in the pathogenesis of SLE. We also discuss new therapeutics targets directed against innate immune components as potential novel therapies in SLE.
- 15 April 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 772
Top Cited PapersOpen AccessInnate Immune Cells' Contribution to Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the presence of autoantibodies against nuclear antigens, immune complex deposition and tissue damage in the kidneys, skin, heart and lung. Because of the pathogenic role of antinuclear antibodies and autoreactive T cells in SLE, extensive efforts have been made to demonstrate how B cells act as antibody-producing or as antigen-presenting cells that can prime autoreactive T cell activation. With the discovery of new innate immune cells and inflammatory mediators, innate immunity is emerging as a key player in disease pathologies. Recent work over the last decade has highlighted the importance of innate immune cells and molecules in promoting and potentiating SLE. In this review, we discuss recent evidence of the involvement of different innate immune cells and pathways in the pathogenesis of SLE. We also discuss new therapeutics targets directed against innate immune components as potential novel therapies in SLE.
- Open Access
- 26 April 2018
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 14 (4) , e1007363
Altered distribution of ATG9A and accumulation of axonal aggregates in neurons from a mouse model of AP-4 deficiency syndrome
The hereditary spastic paraplegias (HSP) are a clinically and genetically heterogeneous group of disorders characterized by progressive lower limb spasticity. Mutations in subunits of the heterotetrameric (ε-β4-μ4-σ4) adaptor protein 4 (AP-4) complex cause an autosomal recessive form of complicated HSP referred to as “AP-4 deficiency syndrome”. In addition to lower limb spasticity, this syndrome features intellectual disability, microcephaly, seizures, thin corpus callosum and upper limb spasticity. The pathogenetic mechanism, however, remains poorly understood. Here we report the characterization of a knockout (KO) mouse for the AP4E1 gene encoding the ε subunit of AP-4. We find that AP-4 ε KO mice exhibit a range of neurological phenotypes, including hindlimb clasping, decreased motor coordination and weak grip strength. In addition, AP-4 ε KO mice display a thin corpus callosum and axonal swellings in various areas of the brain and spinal cord. Immunohistochemical analyses show that the transmembrane autophagy-related protein 9A (ATG9A) is more concentrated in the trans-Golgi network (TGN) and depleted from the peripheral cytoplasm both in skin fibroblasts from patients with mutations in the μ4 subunit of AP-4 and in various neuronal types in AP-4 ε KO mice. ATG9A mislocalization is associated with increased tendency to accumulate mutant huntingtin (HTT) aggregates in the axons of AP-4 ε KO neurons. These findings indicate that the AP-4 ε KO mouse is a suitable animal model for AP-4 deficiency syndrome, and that defective mobilization of ATG9A from the TGN and impaired autophagic degradation of protein aggregates might contribute to neuroaxonal dystrophy in this disorder. Hereditary spastic paraplegia (HSP) is a genetic disorder characterized by progressive stiffness of the legs. To date, mutations in more than 70 genes have been shown to cause HSP. Four of these genes encode the subunits of adaptor protein 4 (AP-4), a heterotetrameric complex involved in intracellular protein trafficking. AP-4 deficiency belongs to a subset of complicated HSPs featuring intellectual disability, seizures, microcephaly and thinning of the corpus callosum in addition to leg stiffness. Here we describe the characteristics of mice lacking the expression of the ε subunit of AP-4. These mice exhibit motor deficits consistent with those seen in the human patients. In addition, they have an abnormally thin corpus callosum and defective axons in various parts of the brain and the spinal cord. Importantly, fibroblasts from AP-4 deficient patients as well as neurons from AP-4 deficient mice fail to deliver the autophagy-related protein 9A (ATG9A) from the Golgi complex to the cell periphery. This defect is associated with accumulation of abnormal protein aggregates in axons from AP-4-deficient neurons. We conclude that AP-4 mutant mice are a suitable animal model for studies of AP-4 deficiency in humans, and that altered localization of ATG9A and aggregate formation in neurons likely contribute to the development of the disease.
- 26 April 2018
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 14 (4) , e1007363
Open AccessAltered distribution of ATG9A and accumulation of axonal aggregates in neurons from a mouse model of AP-4 deficiency syndrome
The hereditary spastic paraplegias (HSP) are a clinically and genetically heterogeneous group of disorders characterized by progressive lower limb spasticity. Mutations in subunits of the heterotetrameric (ε-β4-μ4-σ4) adaptor protein 4 (AP-4) complex cause an autosomal recessive form of complicated HSP referred to as “AP-4 deficiency syndrome”. In addition to lower limb spasticity, this syndrome features intellectual disability, microcephaly, seizures, thin corpus callosum and upper limb spasticity. The pathogenetic mechanism, however, remains poorly understood. Here we report the characterization of a knockout (KO) mouse for the AP4E1 gene encoding the ε subunit of AP-4. We find that AP-4 ε KO mice exhibit a range of neurological phenotypes, including hindlimb clasping, decreased motor coordination and weak grip strength. In addition, AP-4 ε KO mice display a thin corpus callosum and axonal swellings in various areas of the brain and spinal cord. Immunohistochemical analyses show that the transmembrane autophagy-related protein 9A (ATG9A) is more concentrated in the trans-Golgi network (TGN) and depleted from the peripheral cytoplasm both in skin fibroblasts from patients with mutations in the μ4 subunit of AP-4 and in various neuronal types in AP-4 ε KO mice. ATG9A mislocalization is associated with increased tendency to accumulate mutant huntingtin (HTT) aggregates in the axons of AP-4 ε KO neurons. These findings indicate that the AP-4 ε KO mouse is a suitable animal model for AP-4 deficiency syndrome, and that defective mobilization of ATG9A from the TGN and impaired autophagic degradation of protein aggregates might contribute to neuroaxonal dystrophy in this disorder. Hereditary spastic paraplegia (HSP) is a genetic disorder characterized by progressive stiffness of the legs. To date, mutations in more than 70 genes have been shown to cause HSP. Four of these genes encode the subunits of adaptor protein 4 (AP-4), a heterotetrameric complex involved in intracellular protein trafficking. AP-4 deficiency belongs to a subset of complicated HSPs featuring intellectual disability, seizures, microcephaly and thinning of the corpus callosum in addition to leg stiffness. Here we describe the characteristics of mice lacking the expression of the ε subunit of AP-4. These mice exhibit motor deficits consistent with those seen in the human patients. In addition, they have an abnormally thin corpus callosum and defective axons in various parts of the brain and the spinal cord. Importantly, fibroblasts from AP-4 deficient patients as well as neurons from AP-4 deficient mice fail to deliver the autophagy-related protein 9A (ATG9A) from the Golgi complex to the cell periphery. This defect is associated with accumulation of abnormal protein aggregates in axons from AP-4-deficient neurons. We conclude that AP-4 mutant mice are a suitable animal model for studies of AP-4 deficiency in humans, and that altered localization of ATG9A and aggregate formation in neurons likely contribute to the development of the disease.
- 23 August 2017
- Published by Wiley in Immunology
- Vol. 152 (4) , 648-659
Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotype
Summary: Systemic lupus erythematosus (SLE) is an autoimmune disease with unrestrained T‐cell and B‐cell activity towards self‐antigens. Evidence shows that apoptotic cells (ApoCells) trigger an autoreactive response against nuclear antigens in susceptible individuals. In this study, we focus on generating and characterizing tolerogenic dendritic cells (tolDCs) to restore tolerance to ApoCells. Monocyte‐derived dendritic cells (DCs) from healthy controls and patients with SLE were treated with dexamethasone and rosiglitazone to induce tolDCs. Autologous apoptotic lymphocytes generated by UV irradiation were given to tolDCs as a source of self‐antigens. Lipopolysaccharide (LPS) was used as a maturation stimulus to induce the expression of co‐stimulatory molecules and secretion of cytokines. TolDCs generated from patients with SLE showed a reduced expression of co‐stimulatory molecules after LPS stimulation compared with mature DCs. The same phenomenon was observed in tolDCs treated with ApoCells and LPS. In addition, ApoCell‐loaded tolDCs stimulated with LPS secreted lower levels of interleukin‐6 (IL‐6) and IL‐12p70 than mature DCs without differences in IL‐10 secretion. The functionality of tolDCs was assessed by their capacity to prime allogeneic T cells. TolDCs displayed suppressor properties as demonstrated by a significantly reduced capacity to induce allogeneic T‐cell proliferation and activation. ApoCell‐loaded tolDCs generated from SLE monocytes have a stable immature/tolerogenic phenotype that can modulate CD4+ T‐cell activation. These properties make them suitable for an antigen‐specific immunotherapy for SLE.
- 23 August 2017
- Published by Wiley in Immunology
- Vol. 152 (4) , 648-659
Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotype
Summary: Systemic lupus erythematosus (SLE) is an autoimmune disease with unrestrained T‐cell and B‐cell activity towards self‐antigens. Evidence shows that apoptotic cells (ApoCells) trigger an autoreactive response against nuclear antigens in susceptible individuals. In this study, we focus on generating and characterizing tolerogenic dendritic cells (tolDCs) to restore tolerance to ApoCells. Monocyte‐derived dendritic cells (DCs) from healthy controls and patients with SLE were treated with dexamethasone and rosiglitazone to induce tolDCs. Autologous apoptotic lymphocytes generated by UV irradiation were given to tolDCs as a source of self‐antigens. Lipopolysaccharide (LPS) was used as a maturation stimulus to induce the expression of co‐stimulatory molecules and secretion of cytokines. TolDCs generated from patients with SLE showed a reduced expression of co‐stimulatory molecules after LPS stimulation compared with mature DCs. The same phenomenon was observed in tolDCs treated with ApoCells and LPS. In addition, ApoCell‐loaded tolDCs stimulated with LPS secreted lower levels of interleukin‐6 (IL‐6) and IL‐12p70 than mature DCs without differences in IL‐10 secretion. The functionality of tolDCs was assessed by their capacity to prime allogeneic T cells. TolDCs displayed suppressor properties as demonstrated by a significantly reduced capacity to induce allogeneic T‐cell proliferation and activation. ApoCell‐loaded tolDCs generated from SLE monocytes have a stable immature/tolerogenic phenotype that can modulate CD4+ T‐cell activation. These properties make them suitable for an antigen‐specific immunotherapy for SLE.
- 1 February 2016
- Published by Elsevier in Neurobiology of Disease
- Vol. 86, 109-120
Wnt signaling pathway improves central inhibitory synaptic transmission in a mouse model of Duchenne muscular dystrophy
- 1 February 2016
- Published by Elsevier in Neurobiology of Disease
- Vol. 86, 109-120
Wnt signaling pathway improves central inhibitory synaptic transmission in a mouse model of Duchenne muscular dystrophy